Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Sagimet reported positive 52-week open-label extension results from Ascletis' Phase 3 trial of denifanstat in moderate to severe acne, with ~75—80% lesion reductions from original baseline among completers and generally well-tolerated safety, and expects to begin U.S. AURORA Phase 3 screening in Oc…
Sagimet Biosciences said 52-week results from Ascletis’ Phase 3 open-label extension of denifanstat in moderate to severe acne showed 56.7% IGA success, with sustained improvements and no adverse event-related permanent discontinuations reported.
Sagimet says its license partner Ascletis presented positive full 52-week results from a Phase 3 open-label extension clinical trial of denifanstat in acne at EADV 2026.